Three months ago, Envista gave investors almost everything they could reasonably ask for. It raised and narrowed its full-year targets for core growth, adjusted EBITDA and adjusted EPS, cut its expected tax rate and posted its widest year-over-year margin gain in several quarters. The stock has since fallen 17.6%, while the S&P 500 was essentially flat. That gap is the story heading into the third-quarter report on November 4. The question is whether the selloff reflects real cracks in the narrative or simply anxiety about a second half management had already told investors would be slower.

The Street is looking for adjusted EPS of $0.35 on revenue of $686.3 million. That would be roughly 9% earnings growth and 2.5% sales growth from a year ago. Both figures are a sizable step down from the $0.41 and $730.5 million reported in the second quarter. Part of that is by design. Management guided second-half revenue growth below the first half and said second-half EBITDA would grow roughly in line with sales. It also flagged that a $5 million deferral benefit from the SPARC business recognized in the second quarter would not repeat. The full-year guide of $1.50 to $1.55 implies second-half EPS of about $0.73 to $0.78. A $0.35 third quarter fits comfortably within that math. The more curious signal is the full-year consensus of $1.42, which sits below the bottom of management's EPS range. The Street's $2.86 billion revenue estimate, meanwhile, sits above the company's $2.81 billion to $2.84 billion range. Some of that mismatch likely reflects stale estimates. Still, it suggests analysts have not fully embraced the margin story, even as they lean optimistic on sales.

Margins are where the report can earn its keep. Envista turned 5% core growth into 28% EBITDA growth last quarter, with the Equipment & Consumables segment doing the heavy lifting. Core growth there was 8.5%, the fifth straight quarter of high-single-digit or better gains, and operating margin improved 250 basis points. If consumables and diagnostics keep growing at that pace without the SPARC tailwind, the guidance raise looks conservative. If E&C cools toward the company's overall low-single-digit rate, the second-half deceleration could prove more than a calendar effect.

China is the swing factor investors cannot model cleanly. Volume-based procurement processes for orthodontics and implants were confirmed as underway and expected to wrap up in the second half. Management talked about price cuts of roughly 40% to 45% in ortho and 10% to 15% in implants, and left the net benefit from the implant round unresolved. Any early detail on volume gains offsetting those price cuts will matter more than the headline quarter. The same goes for the implant business itself, where core growth has hovered in the low single digits. The Nobel S-Series launch was tracking ahead of plan, with about a quarter of placements coming from competitive conversions, and the Versa osseodensification deal was also running ahead of expectations. Evidence that these products are lifting implant growth, particularly in a North American market management called relatively soft, would directly counter the bear case.

Sentiment has cooled noticeably, slipping to a barely positive reading from a more constructive level before the last report. The stock trades around $23.66, below its 200-day moving average of $25.72 and much closer to its post-earnings low of $22.20 than its $29 high. That is a low bar for a company that just raised guidance. But a soft fourth-quarter outlook could still push the shares to fresh lows, since management has already warned of a four-billing-day headwind in that period.

Ultimately, this report needs to show that last quarter's margin expansion was structural rather than a product of easy comparisons and one-time help. Reaffirming the $1.50 to $1.55 range while E&C momentum holds would go a long way toward closing the gap between the improving fundamentals and the deteriorating stock. Clarity on China VBP economics would help close it further.